Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.34 USD
Change Today -0.08 / -0.43%
Volume 4.8M
BSX On Other Exchanges
New York
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/15 - $18.49
52 Week Low
10/16/14 - $11.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

24,000 Employees
Last Reported Date: 02/25/15
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $921.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $450.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Executive Vice President and President of Rhy...
Total Annual Compensation: $454.1K
Senior Vice President and President of Interv...
Total Annual Compensation: $392.8K
Compensation as of Fiscal Year 2014.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Enters into $2,000,000,000 Senior Unsecured Credit Facility

On April 10, 2015, Boston Scientific Corporation entered into a $2,000,000,000 senior unsecured credit facility, by and among the company, as Borrower, the several lenders party thereto, Bank of America, N.A., as Syndication Agent and JPMorgan Chase Bank, N.A., as Administrative Agent. The 2015 Credit Agreement refinances the Company’s prior credit agreement, dated as of April 18, 2012, by and among the company, as Borrower, the several lenders party thereto, Bank of America, N.A., as Syndication Agent and JPMorgan Chase Bank, N.A., as Administrative Agent (the 2012 Facility). The company may borrow from time to time up to $2,000,000,000 in revolving credit loans under the 2015 Credit Agreement. The 2015 Credit Agreement matures on April 10, 2020, with one-year extension options subject to certain conditions, including certain lender approvals. Loans under the 2015 Credit Agreement will bear interest at the company’s option at either LIBOR or ABR plus an interest margin. ABR is the great of the (a) Prime Rate, (b) the Federal Funds Effective Rate plus ½ of 1% per annum and (c) one month LIBOR plus 1% per annum.

Boston Scientific Signs Strategic Alliance with Frankenman Medical Equipment Company

Boston Scientific Corporation announced the signing of a strategic alliance with Frankenman Medical Equipment Company. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership. Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The companies have agreed to work together to develop and manufacture products in China to better serve the unique needs of the Chinese market, as well as jointly commercialize selected products in China.

Boston Scientific Corporation Receives FDA and CE Mark Approval for EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System

Boston Scientific Corporation announced that it has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest (SCA), yet leaves the heart and vasculature untouched, minimizing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators (TV-ICDs).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $18.34 USD -0.08

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $144.33 USD -0.02
Olympus Corp ¥4,510 JPY +15.00
St Jude Medical Inc $73.47 USD -0.54
Stryker Corp $96.90 USD -0.28
Zimmer Holdings Inc $118.76 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 3.8x
Price/Cash Flow 77.0x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at